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Spasticity often has a negative impact on
motricity and the locomotor system but may
not always be problematic and can even be useful
in some cases. Not all spastic patients necessarily
require treatment.
Spasticity must be analyzed as a symptom by
using the same approach, regardless of the
aetiology.
The medical context (notably influenced by the
condition’s aetiology) must then be taken into
account as part of an overall treatment strategy.
Spasticity treatment must only be initiated after
rigorous clinical analysis, in order to determine
the condition’s intensity, true consequences and
distribution. This presupposes a good degree of
knowledge and investigational rigour.
A list of personal objectives must be drawn up for
each patient.
Treatment first necessitates identification of any
aggravating factors or nociceptive stimuli (bed
sores, urinary infection or lithiasis, etc.) with
which the spasticity is sometimes tightly inter-
meshed.
The therapeutic strategy should encompass not
only the drug treatments presented here but also
physiotherapy, the use of orthoses and technical
aids, self-rehabilitation and surgery.
Drug treatments include orally administered
compounds (baclofen and tizanidine), botulinum
toxin, intrathecal baclofen and the local applica-
tion of alcohol or phenol. Choice of the first-line
treatment (orally administereddrugsorbotulinum
toxin) will depend on the localized or extended
nature of spasticity and on the aetiology.
1. Introduction
The following AFSSAPS’s guidelines have been produced by
a working group of experts in the field of spasticity treatment. An
exhaustive analysis of the literature was performed. Each article
was discussed by the expert committee and then selected and
classified according to the standard criteria recommended by
France’s Drug Authority (AFSSAPS). The result is the fruit of the
critical review of these articles and, when literature data were
insufficient, the expert committee’s discussions.
Whatever its aetiology, spasticity usually has a negative
impact on motricity and the locomotor system; this justifies
treatment of the symptom itself (i.e. independently of the
aetiological context) as a function of the patient’s neurological
disorders and any links between the latter.
Treating spasticity can only be envisaged after rigorous
clinical analysis, in order to determine the condition’s intensity,true consequences and distribution. This presupposes a good
degree of knowledge and investigational rigour.
Evaluating the real impact of spasticity is essential. The
measurement of spasticity in a patient at rest does not reflect the
condition’s impact during movement.
Spasticity is subject to variations due to a number of
different factors; the main one is the patient’s body position and
activity because the condition predominantly affects weight-
bearing muscles and thus becomes more intense in the standing
position.
Only the most detailed possible analysis of the impact of
spasticity in all its functional aspects enables the practitioner to
decide on the appropriateness of a given treatment and to set
reasonable patient objectives in terms of function, comfort,
hygiene and pain relief.
Evaluation of spasticity is performed on two levels:
 the symptom itself: hypertonia is measured on the Ashworth
scale (which is most frequently used) or the Tardieu scale
(which is more appropriate); the spasms are measured on the
Penn scale;
 the impact of the symptom:
 joint amplitudes, as measured by goniometry,
 pain on a visual analogue scale,
 impairment noted during nursing on scales intended for
caregivers or the patient him/herself (the Disability
Assessment Scale, for example),
 impairment of active movement on clinical scales (the Box
and Block test, the Motor Activity Log or the Frenchay
Arm Test to evaluate prehension; speed and distance tests to
evaluate gait, for example) and using very useful
instrumental analysis (notably kinematic analyses).
Generic personal independence scales (such as the Barthel
Index and the Functional Independence Measure) are too
general to enable measurement of the effects of treatments.
A list of personal objectives must be drawn up for each
patient; these must be evaluable separately, after having
untangled the various components of the motor disorder and
having evaluated as accurately as possible their respective
contributions to the functional impairment. The therapeutic
strategy is based on this objective-driven approach. Not all
spastic patients necessarily require treatment.
The examination must answer the following three questions:
 is spasticity problematic and, if so, in what respects? This is
the key question;
 is spasticity the main cause of the disability or only one of the
components? In the latter case, which components are
involved? The likelihood of a successful treatment outcome
depends on the answer to these questions;
 is the problematic spasticity limited to one muscle group or
spread more widely? Again, choosing the right treatment
depends on the answer.
This clinical analysis can be usefully supported by an
instrumental analysis (notably kinematic analysis) and by the
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by-case basis) the diagnosis of muscle retraction or a movement
analysis.
Moreover, treatment must also address potential aggravating
causes (bed sores, urinary infection or lithiasis, etc.), with
which the spasticity is sometimes tightly intermeshed; the so-
called ‘‘nociceptive triggering factors increases spasticity (even
in anesthetized and paralysed zones) but treatment of the latter
also sometimes help to treat the nociceptive stimulus (sores,
pain, etc.).
These guidelines only cover drug treatments, although the
latter should generally be considered as just one component of a
therapeutic programme that combines (to a varying extent)
physiotherapy (which remains the basic treatment for all spastic
patients), ergotherapy, the use of an orthosis and technical aids,
auto-rehabilitation, orthopaedic surgery and neurosurgery.
Specialists in physical and rehabilitation medicine are at the
heart of this management strategy, in collaboration with the
rehabilitation team, neurosurgeons, orthopaedic surgeons,
neurologists and paediatricians.
These guidelines address each drug separately and then
suggest a decision tree for each type of pathology in the form of
algorithms and tables which summarize the dual approach that
is required (site-driven and objective-driven). The drugs
mentioned in the text are presented in an Appendix.
2. Botulinum toxin type A
Botulinum toxin type A is recommended because there is
established scientific evidence of its efficacy in the local
reduction of spasticity after intramuscular injection (Grade A).
It can be used as a first-line treatment of spasticity when the
objective is focal or multifocal ( professional consensus).
In adults, most of the results come from studies on stroke
patients and, in children, from studies on patients with cerebral
palsy. However, the use of botulinum toxin can be envisaged
regardless of the pathology in question ( professional consen-
sus), since the indication is more symptomatic than aetiolo-
gical. This is what is anticipated in the product marketing
approval (PMA) granted by the French health authorities in
adults, although the same approach can be adopted in children.
Botulinum toxin type B may have the same effects but there
are currently too few studies to draw reliable conclusions. It is
available on the market (as Neurobloc1) but does not have a
PMA for this indication.
2.1. The efficacy of botulinum toxin type A
In adults, one observes:
 an improvement in self-care (washing and dressing) (level of
evidence 1 for the arms and the legs);
 an improvement in active motricity in the leg in particular and
in gait in general (level of evidence 2).
Changes in active function of the arm have not been
observed.In children, one observes:
 an improvement in active arm or leg function, (level of
evidence 2);
 an effect on pain (level of evidence 2).
The prevention of orthopaedic deformation is an important
objective and should prompt very early-stage treatment in
children.
It should be noted that an antalgic effect per se has not been
demonstrated; however, the painful consequences of spasticity
are reduced.
2.2. Dose
The units differ, there are no international units and there is
no recognised equivalence. There is no information concerning
the dilution which would enable recommendation of practices
other than those covered in the PMA:
 1 ml for Botox1, 100 Allergan U/ml;
 2.5 ml for Dysport1, 500 Speywood U/1 to 2.5 ml.
Intramuscular injection is performed, while ensuring that
injection into a vessel does not occur.
The recommended total maximum dose is as follows:
 in adults: 500 Allergan U for Botox1 and 1,500 Speywood U
for Dysport1;
 in children: 20 Allergan U/kg for Botox1 and 30 Speywood
U/kg for Dysport1 ( professional consensus);
 the recommended maximum dose of Botox1 per session is
higher than the ceiling dose in the PMA. However, this
overshoot appears to be justified when multifocal treatment is
required ( professional consensus).
The recommended doses per muscle differ slightly from those
presented in the PMA. By way of an example, three different
maximum doses are suggested for three different muscle groups,
according to their size ( professional consensus).
Botox1
Allergan
Dysport1
Speywood
Units Units
Large muscles, such as the
triceps surae
400 1,000
Medium-sized muscles, such
as the flexor carpi radialis
100 300
Small muscles, such as the
interosseous muscles
20 50
For the first injection, lower initial doses are recommended –
especially so in patients with comorbidities ( professional
consensus).
2.3. Safety of use
Injection site localization techniques based solely on
anatomical markers are not recommended ( professional
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mended localization technique ( professional consensus).
A diagnostic electromyogram alone is not sufficient for
identifying the muscle. Ultrasound guidance can be used to
identify muscles that cannot be accessed via stimulation or non-
stimulable muscles or in children, since the technique is
painless.
The number of injection sites depends on the muscle’s
structure and size.
Treatment of patients on antiplatelet agents is possible. As
for all intramuscular injections, it is not advisable to inject a
patient taking effective doses of an anticoagulant ( professional
consensus).
The use of analgesics is recommended, either locally and/or
systemically (local anaesthesia or nitrous oxide) ( professional
consensus). Oral premedication can be used, notably in children
( professional consensus).
According to good clinical practice, one must distinguish
between the patient information consultation and the session
during which the injection is performed; this provides the
patient with time to think things over.
Monitoring immediately after the injection is not necessary,
except in rare cases where general anaesthesia is essential
( professional consensus). No immediate post-injection compli-
cations (apart from pain at the injection site) have been
reported.
In children, some rare cases require general anaesthesia –
essentially injection into poorly accessible, deep muscles or in
the event of behavioural disorders or resistance to antalgics (see
the guidelines issued by the French Society for Anaesthesia and
Intensive Care). Greater caution is recommended in multi-
diseased children with swallowing and/or respiratory disorders.
Traceability of the injected product is strongly recommen-
ded: the batch number, the overall dose, the dose per muscle and
the dilution.
It is advisable to evaluate the results of the therapy in a
consultation 3 to 6 weeks after the first injection. Any
subsequent injection should also be followed by an evaluation.
Repeat injections are justified by the toxin’s transient effect.
The indication of repeat injections (with at least 3 months
between injections) should be evaluated according to the
benefits and the tolerance, with a review of the dose and the
treated muscles. Repeat injections can be continued as long as
beneficial effects are observed after each administration. Other
long-term therapeutic alternatives (notably surgery) should be
envisaged.
There is not enough information to justify recommendation
of antibody assays.
The use of a follow-up diary and a patient information sheet
is recommended.
The patient and his/her family must be warned of the low but
potential risk of adverse effects that can occur during the first 3
weeks after each injection (swallowing disorders and botuli-
num syndrome) and should be encouraged to consult if in any
doubt ( professional consensus).
Pharmacovigilance studies have not reported any harmful
effects of long-term use but the literature does not describecohort follow-up beyond 2 years. Adverse events must be
systematically noted and reported to the pharmacovigilance
services.
Lack of treatment efficacy should prompt practitioners to
question the indications and/or the technique. A repeated lack
of efficacy means that treatment must be withdrawn, even in the
absence of other therapeutic alternatives ( professional consen-
sus).
For injection, prior theoretical and practical training on both
the indications and the technique is recommended.
3. Orally administered treatments
3.1. In adults
Two orally administered compounds treatments (baclofen
and tizanidine) have shown proven efficacy in reducing
spasticity on the Ashworth muscle hypertonia scale.
Tizanidine has received a temporary authorization of use
(TAU) in France: it is recommended when baclofen is
ineffective, contra-indicated or produces adverse effects
( professional consensus).
These compounds are not recommended as first-line
treatments after a recent stroke, due to their insufficient
efficacy and adverse effects. They are recommended as first-
line treatments in multiple sclerosis (MS) and spinal cord
injury-related spasticity (Grade B).
Other molecules (such as dantrolene) have received
marketing approval but the age of the studies and insufficient
levels of evidence prevent their recommendation on the basis of
the literature data.
A number of compounds that lack marketing approval (such
as clonazepam and tetrazepam) are used in routine practice.
However, there is no literature evidence to support this use.
3.1.1. Efficacy of oral baclofen and tizanidine
A limited number of studies are available. Efficacy is dose-
dependent.
There is no evidence that baclofen and tizanidine reduce the
functional impact of spasticity. The therapeutic approach must
be first local or regional and these treatments must be reserved
for problematic, widespread spasticity ( professional consen-
sus).
3.1.2. Dose
Introduction and adaptation must take place progressively,
depending on the efficacy and any adverse effects. All long-
term treatments (in a stabilized or non-stabilized patient) must
always be reappraised with a periodicity that depends on the
condition and its time since onset. Depending on the situation,
this reappraisal may include a therapeutic window created by
progressively decreasing or increasing the dose.
Regarding the dose of baclofen, it is advisable to remain
within the limits set in the marketing authorization (no more
than 120 mg per day).
Withdrawal must be progressive and the patient should be
warned that if the symptoms worsen, the treatment must be
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dose reduction must be:
 10 to 15 mg per week for baclofen;
 4 mg per week for tizanidine ( professional consensus).
3.1.3. Precautions for use
It is best to consider that the GABAergic agents (baclofen
and benzodiazepines) may have a harmful effect on the body
during the recovery phase, as has been observed in animal
models. This should prompt great caution in patients in the
recovery phase (in acute-phase stroke or during an MS relapse).
There is no evidence that a baclofen-tizanidine combination
(or any other combination of oral agents) is of value.
3.2. In children
Only baclofen has marketing approval (from the age of 6
upwards). However, the data do not support its use.
Diazepam is frequently used in this indication, despite the
absence of a PMA. It can be recommended (Grade B), although
its GABAergic action should prompt caution and short periods
of use (harmful effects on the growing body and in the recovery
phase have been observed in animal models) ( professional
consensus).
There is no evidence to suggest that other non-approved
molecules that sometimes used (such as tetrazepam) are
effective.
4. Intrathecal baclofen (ITB)
Intrathecal baclofen is an effective treatment for spasticity. It
can notably be recommended in spinal injury patients and in
MS (Grade A). It is a long-term treatment with continuous,
intra-spinal administration via an implanted pump.
It is mainly recommended for patients whose spasticity of
the legs is broadly distributed and sometimes extends to the
trunk (Grade A).
4.1. Efficacy of intrathecal baclofen
Intrathecal baclofen should be reserved for spasticity which:
 interferes with posture, nursing and rest;
 interferes with personal independence or gait;
 causes pain (professional consensus).
A favourable effect on autonomous hyperreflexia can be
expected in spinal injury patients.
4.2. Precautions for use
The presence of osteosynthetic material in or near the spine
or the presence of bed sores are not formal contra-indications
( professional consensus).
It is necessary to ensure good patient compliance with the
treatment constraints ( professional consensus).The patient and/or his/her family and friends must always be
provided with detailed information on the expected benefits and
possible risks, notably in terms of the risk of loss of motor
function (which can be reversed when treatment is withdrawn).
In children, spinal development should be monitored very
closely.
One or more tests (simple injection by lumbar puncture or
via a temporary access device) must be performed before
implantation of a pump.
The physician who performs the injection must evaluate its
efficacy in the following 3 to 4 hours ( professional consensus).
4.3. Dose
The usually recommended first test dose is 50 mg in adults
and 25 mg in children (Grade B).
The maximum dose for a test must not exceed 150 mg in
adults and 100 mg in children and should be reached after 3 and
4 days, respectively (Grade B). The patient’s maintenance dose
can range from 20 mg to 1,500 mg.
There is usually a requirement to increase the dose in the first
6 to 9 months post-implantation ( professional consensus).
However, this increase must not be considered as related to a
tolerance phenomenon but rather as an adaptation to the clinical
state.
4.4. Safety of use
The inherent risk in intrathecal baclofen injection is
overdosing (vigilance and respiratory disorders). Monitoring
(notably of vital signs) by a specialist team must be performed
during the 3 hours following the test.
Implantation of the pump, monitoring and follow-up must be
performed by a specialist medical and surgical team. It is
important to perform maintenance – notably to detect hazards
related to the procedure (displacement of the catheter,
infection, etc.) and prevent the occurrence of a cessation
syndrome. The patient does not necessarily have to have
received oral baclofen prior to implantation of a pump.
5. Alcohol and phenol
Alcohol and phenol reduce spasticity (evaluated on the
Ashworth scale) by chemical neurolysis (irreversible destruc-
tion of the nerve).
These local treatments should not be used on a first-line
basis, except in certain cases of particularly widespread and
problematic spasticity in which they can sometimes be
combined with another local treatment (botulinum toxin)
( professional consensus).
In children, extreme caution is recommended in subjects
under the age of 10 but these treatments can be used (for the
nerve contact only) and especially for the obturator nerve, while
concentrating on trophic and comfort-related parameters
( professional consensus).
It should be noted that neither phenol nor alcohol has
marketing approval in this indication. Only glycerine phenol
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pharmaceutical units managed by French public-sector
healthcare facilities) in the treatment of severe spasticity,
although the AFSSAPS has not evaluated this.
5.1. Efficacy of alcohol and phenol
If the first injection does not provide the expected benefit, this
must be considered as failure of the treatment and another type of
therapy must then be considered ( professional consensus).
5.2. Alcohol or phenol?
Glycerine phenol is preferable to normal phenol: the latter
diffuses more rapidly and is thus less well tolerated
( professional consensus). There are no arguments in favour
of phenol, compared with alcohol.
5.3. Precautions for use
Local injection must be performed during electrostimulation
or ultrasound guidance ( professional consensus). It should only
be performed by specialist medical teams.
Intramuscular alcohol or phenol administration must be
prohibited, due to irreversible muscle damage ( professional
consensus).
Nerves with a low sensory activity and high motor
predominance can be treated (obturator, cutaneo-muscular,
etc.) ( professional consensus). The treatments of mixed nerves
(the body of the ischiatic nerve, the posterior tibial and fibular
nerves in the leg and the median and ulnar nerves in the arm) is
strictly prohibited, in view of the risk of sensory disorders
( professional consensus).
It is advisable to perform a motor block before treatment in
order to check that the latter is effective ( professional consensus).
The benefits of alcohol or phenol treatment must be initially
weighed up, relative to those of surgery. In fact, alcohol
treatment induces fibrosis from the very first injection onwards,
making subsequent surgery more difficult. Hence, prior to a
second course of alcohol treatment, surgery should be
considered - notably if a selective neurotomy is envisaged
( professional consensus). Iterative alcohol treatment may not
complicate subsequent neurectomy.
The patient and/or his/her family and friends must always be
provided with detailed information on the expected benefits and
possible risks.5.4. Dose
There are no studies on the dose for injection. Injections
must be performed with electrostimulation, once the site has
been determined at an intensity below 0.5 milliamps, in
compliance with good practice for local and regional
anaesthetic blocks ( professional consensus).
The closer the nerve, the lower the volume.
5.5. Safety of use
This is a potentially painful act and so local or general
analgesia should be considered.
Treatment of patients on antiplatelet agents is possible. As
for all intramuscular injections, it is not advisable to inject a
patient taking effective doses of an anticoagulant.
6. General therapeutic strategy
Once the problematic nature of the spasticity has been
confirmed:
 the drug treatment of spasticity cannot be envisaged in the
absence of other therapeutic modalities;
 physiotherapy is the basic treatment. It often helps avoid
muscle retractions but cannot attenuate spasticity in the long
term;
 drug treatment can be envisaged:
 as soon as spasticity is seen to be problematic (and
before waiting for potential stabilization of the condi-
tion),
 after have eliminated a possible aggravating, nociceptive
cause,
 after have agreed on precise objectives with the patient,
 as a function of the localized or widespread nature of the
spasticity,
 when favouring a focal approach,
 when guided by the performance of a motor block test;
 temporary immobilisation in a posture brace is sometimes
useful (notably in children after focal treatment). Careful
monitoring is required (notably the status of the skin);
 if correctly administered treatment is ineffective, surgical
approaches must be considered.
Algorithms concerning the management of the most
frequent spastic situations are presented below.
6.1. Lexicon
ITB: intrathecal baclofen
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